AIxplorerBio launched its molecular design and optimization platform, AIxMolTM, to accelerate AI-enabled new drug R&D pipeline

Source:AIxplorerBio Time:2022-08-22

On August 22, AIxplorerBio announced that the company had successfully launched AIxMolTM, its molecular design and optimization platform. AIxMolTM is committed to empowering internal drug development pipeline by combining Artificial Intelligence (AI) with Computer-Aided Drug Design (CADD), providing full-process and efficient solutions for hit discovery and lead optimization.